Skip to main content
ADCT $1.25 -3.78%
ADCT logo
ADCT · ADC Therapeutics SA
Track ADCT — free
$1.25 -0.05 (-3.78%) Q1 2026 earnings call transcript
Market Cap
$165.97M
Shares
127.67M
Volume · Nov 19 752.42K Avg daily vol (3M) 1.57M
All webcasts

Earnings call · FY2026 Q3

ADC Therapeutics SA (ADCT) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $21.72M +32.2% YoY
Diluted EPS -$0.16
Net income -$25.30M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
ADC Therapeutics reported third-quarter net product revenue of $21.0 million and net loss of $25.3 million. Its October 2026 restructuring included an $86.6 million PIPE and extends expected cash runway into 2029.
10-Q report · filed Nov 9, 2026
ADC Therapeutics reported that Phase 3 LOTIS-5 showed significantly improved progression-free survival with ZYNLONTA plus rituximab versus R-GemOx in 420 patients; median PFS was 6.14 months versus 4.73 months.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$21.01M +33.4% YoY
Royalty Revenue$710,000 +4.9% YoY
License Revenues$0
Full-screen source Call document